NOT-AI-16-052: Notice of NIAID's Participation in PA-16-183 "Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)"

Notice of NIAID's Participation in PA-16-183 "Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)"

Notice Number: NOT-AI-16-052

Key Dates
Release Date: May 16, 2016

Related Announcements
PA-16-183

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform potential applicants of the National Institute of Allergy and Infectious Diseases (NIAID) participation, effective immediately, in the Funding Opportunity Announcement (FOA), PA-16-183, entitled "Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)" limited to U01 applications only.

PA-16-183 has been updated in the following ways to reflect NIAID's participation in this FOA.

Part 1. Overview

Components of Participating Organizations

National Center for Advancing Translational Sciences (NCATS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.350, 93.855, 93.856, 93.847, 93.846

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Michael Minnicozzi, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 301-496-7074
Email: minnicozzim@niaid.nih.gov